FDA Targets GLP 1 and Peptide Compounding, Advertising and 'Research Use Only' Labeling The FDA has issued clear signals on BPC 157: it is not approved for human use in any form due to potential significant safety risks. This critical classification profoundly impacts research and In a major policy shift, the U.S. Food and Drug Administration is reconsidering restrictions on several controversial peptides, including trending compounds like BPC 157 and Melanotan II. The move comes as demand for The peptide problem: Hype is outrunning the evidence Q&A: Should you trust trending peptide injections?